Sernova Biotherapeutics Inc (TSX:SVA)
Canada · Delayed Price · Currency is CAD 0.1100
-0.0050 (-4.35%)
Sep 4, 2026, 3:10 PM EST
Sernova Biotherapeutics Cash Flow Statement
Financials in millions CAD. Fiscal year is November - October.
Millions CAD. Fiscal year is Nov - Oct.
Operating Activities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Apr '26 Apr 30, 2026 | Oct '25 Oct 31, 2025 | Oct '24 Oct 31, 2024 | Oct '23 Oct 31, 2023 | Oct '22 Oct 31, 2022 | Oct '21 Oct 31, 2021 |
Net Income | -11.91 | -15.74 | -32.19 | -39 | -24.42 | -6.97 |
Depreciation & Amortization | 0.26 | 0.34 | 0.54 | 0.45 | 0.44 | 0.27 |
Loss (Gain) From Sale of Assets | -0.06 | -0.06 | -0.02 | - | - | - |
Stock-Based Compensation | 2.44 | 2.51 | 1.75 | 3.9 | 7.45 | 0.22 |
Other Operating Activities | 0.77 | 0.31 | -0.13 | -0.68 | -0.84 | -0.88 |
Change in Accounts Receivable | 0.32 | 0.18 | 0.56 | 0.23 | -0.2 | -0.09 |
Change in Accounts Payable | 2.55 | 1.54 | 10.59 | 4.75 | 3.31 | 0.46 |
Change in Other Net Operating Assets | 0.13 | 0.02 | 0.01 | 0 | -0.16 | 0.14 |
Operating Cash Flow | -5.5 | -10.91 | -18.9 | -30.34 | -14.42 | -6.84 |
Operating Cash Flow Growth | - | - | - | - | - | - |
Investing Activities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Apr '26 Apr 30, 2026 | Oct '25 Oct 31, 2025 | Oct '24 Oct 31, 2024 | Oct '23 Oct 31, 2023 | Oct '22 Oct 31, 2022 | Oct '21 Oct 31, 2021 |
Capital Expenditures | - | - | - | -0.1 | -0.33 | -0.02 |
Sale of Property, Plant & Equipment | 0.02 | 0.02 | - | - | - | - |
Investment in Securities | - | - | 11.08 | 34.92 | -46 | - |
Other Investing Activities | - | - | 0.04 | -0.04 | -0.01 | -0.21 |
Investing Cash Flow | 0.02 | 0.02 | 11.12 | 34.78 | -46.34 | -0.23 |
Financing Activities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Apr '26 Apr 30, 2026 | Oct '25 Oct 31, 2025 | Oct '24 Oct 31, 2024 | Oct '23 Oct 31, 2023 | Oct '22 Oct 31, 2022 | Oct '21 Oct 31, 2021 |
Long-Term Debt Issued | - | 4.94 | - | - | - | - |
Long-Term Debt Repaid | - | -0.11 | -0.17 | -0.17 | -0.17 | -0.03 |
Lease Payments | -0.03 | -0.11 | -0.17 | -0.17 | -0.17 | -0.03 |
Net Debt Issued (Repaid) | -2.28 | 4.82 | -0.17 | -0.17 | -0.17 | -0.03 |
Issuance of Common Stock | 6.82 | 0.27 | 5.23 | - | 36.55 | 27.55 |
Other Financing Activities | -0.02 | 0.05 | 0.01 | 0.68 | 0.28 | 3.47 |
Financing Cash Flow | 4.53 | 5.14 | 5.07 | 0.5 | 36.66 | 31 |
Net Cash Flow
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Apr '26 Apr 30, 2026 | Oct '25 Oct 31, 2025 | Oct '24 Oct 31, 2024 | Oct '23 Oct 31, 2023 | Oct '22 Oct 31, 2022 | Oct '21 Oct 31, 2021 |
Net Cash Flow | -0.94 | -5.75 | -2.71 | 4.95 | -24.1 | 23.92 |
Free Cash Flow
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Apr '26 Apr 30, 2026 | Oct '25 Oct 31, 2025 | Oct '24 Oct 31, 2024 | Oct '23 Oct 31, 2023 | Oct '22 Oct 31, 2022 | Oct '21 Oct 31, 2021 |
Free Cash Flow | -5.5 | -10.91 | -18.9 | -30.44 | -14.75 | -6.86 |
Free Cash Flow Growth | - | - | - | - | - | - |
Free Cash Flow Per Share | -0.02 | -0.03 | -0.06 | -0.10 | -0.05 | -0.03 |
Levered Free Cash Flow | -15.61 | -5.66 | -6.65 | -16.13 | -5.56 | -3.19 |
Unlevered Free Cash Flow | -14.56 | -5.19 | -6.29 | -16.11 | -5.53 | -3.18 |
Free Cash Flow After Leases | -5.53 | -11.02 | -19.07 | -30.61 | -14.92 | -6.89 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Apr '26 Apr 30, 2026 | Oct '25 Oct 31, 2025 | Oct '24 Oct 31, 2024 | Oct '23 Oct 31, 2023 | Oct '22 Oct 31, 2022 | Oct '21 Oct 31, 2021 |
Cash Income Tax Paid | 0 | 0.01 | - | - | - | - |
Change in Working Capital | 3 | 1.74 | 11.16 | 4.99 | 2.95 | 0.52 |